JP Morgan Maintains Overweight on Dyne Therapeutics, Raises Price Target to $22
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Tessa Romero maintains an Overweight rating on Dyne Therapeutics (NASDAQ:DYN) and raises the price target from $20 to $22.
August 09, 2023 | 4:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Dyne Therapeutics and raises the price target from $20 to $22, indicating a positive outlook for the company.
The raised price target by JP Morgan indicates a positive outlook for Dyne Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100